Cancer cell surface protein

The term "Cancer cell surface protein" is not a specific molecular target but rather a broad, non-specific category referring to any protein expressed on the surface of cancer cells. These proteins are of significant interest in oncology because they can serve as markers for disease and as targets for therapies such as antibody-drug conjugates (ADCs), chimeric antigen receptor T cells (CAR-T), bispecific antibodies, and other immunotherapies[1][3][5]. However, "cancer cell surface protein" does not refer to a single molecule; instead, it encompasses hundreds of distinct proteins—such as HER2 (ERBB2), CD276 (B7-H3), EPCAM, TACSTD2 (TROP2), NECTIN4, FOLR1, and many others—that have been identified across various tumor types[3][4]. Each individual cancer cell surface protein has its own canonical name, abbreviation(s), biological function(s), disease association(s), interacting drugs, mechanisms of action for targeted therapies, biomarker status, and safety profile. Because the query refers only to the general class ("Cancer cell surface protein") rather than a specific molecule or gene product: - There is no unique canonical name or abbreviation. - It cannot be directly classified into standard molecular families beyond "Other." - No specific aliases apply. - No single set of interacting drugs or mechanisms can be listed. - Safety concerns cannot be meaningfully addressed without specifying which particular protein is meant. For structured data extraction or drug development purposes in oncology research and clinical practice, it is essential to specify the exact target by its full scientific name (e.g., "Epithelial cell adhesion molecule," abbreviated EPCAM) rather than using this generic phrase[1][3][6].